Patents by Inventor Irina Mirkina
Irina Mirkina has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230365671Abstract: The invention refers to anti-oxMIF antibodies with improved properties such as reduced aggregation potential and reduced hydrophobicity due to selected amino acid substitutions in the light and heavy chain variable domains and optionally increased effector functions due to further substitutions in the heavy chain constant regions, and their use in the treatment of oxMIF-related conditions.Type: ApplicationFiled: October 1, 2021Publication date: November 16, 2023Inventors: Alexander SCHINAGL, Irina MIRKINA, Randolf KERSCHBAUMER, Robert Michael THIELE
-
Publication number: 20230277643Abstract: The subject relates to an isolated antibody that specifically binds to O25b antigen of multi drug resistant (MDR) E. coli strains, its medical and diagnostic use, method of producing the antibody, including an isolated nucleotide sequence, plasmids and host cells as used in the production of the antibody; and further an isolated epitope recognized the specific antibody.Type: ApplicationFiled: November 22, 2022Publication date: September 7, 2023Inventors: Eszter NAGY, Gábor NAGY, Valéria SZIJÁRTO, Zóltan MAGYARICS, Irina MIRKINA, Luis GAUCHALLA, Adriana BADARAU, Gerhild ZAUNER, Jolanta LUKASIEWICZ
-
Patent number: 11529405Abstract: The subject relates to an isolated antibody that specifically binds to O25b antigen of multi drug resistant (MDR) E. coli strains, its medical and diagnostic use, method of producing the antibody, including an isolated nucleotide sequence, plasmids and host cells as used in the production of the antibody; and further an isolated epitope recognized the specific antibody.Type: GrantFiled: February 4, 2021Date of Patent: December 20, 2022Assignee: Janssen Pharmaceuticals, Inc.Inventors: Eszter Nagy, Gäbor Nagy, Valéria Szijárto, Zóltan Magyarics, Irina Mirkina, Luis Gauchalla, Adriana Badarau, Gerhild Zauner, Jolanta Lukasiewicz
-
Publication number: 20210162034Abstract: The subject relates to an isolated antibody that specifically binds to O25b antigen of multi drug resistant (MDR) E. coli strains, its medical and diagnostic use, method of producing the antibody, including an isolated nucleotide sequence, plasmids and host cells as used in the production of the antibody; and further an isolated epitope recognized the specific antibody.Type: ApplicationFiled: February 4, 2021Publication date: June 3, 2021Applicant: X4 PHARMACEUTICALS (AUSTRIA) GMBHInventors: Eszter NAGY, Gábor NAGY, Valéria SZIJÁRTO, Zoltán MAGYARICS, Irina MIRKINA, Luis GUACHALLA, Adriana BADARAU, Gerhild ZAUNER, Jolanta LUKASIEWICZ
-
Patent number: 10940191Abstract: The subject relates to an isolated antibody that specifically binds to O25b antigen of multi drug resistant (MDR) E. coli strains, its medical and diagnostic use, method of producing the antibody, including an isolated nucleotide sequence, plasmids and host cells as used in the production of the antibody; and further an isolated epitope recognized the specific antibody.Type: GrantFiled: December 21, 2018Date of Patent: March 9, 2021Assignee: X4 PHARMACEUTICALS (AUSTRIA) GMBHInventors: Eszter Nagy, Gábor Nagy, Valéria Szijárto, Zoltán Magyarics, Irina Mirkina, Luis Guachalla, Adriana Badarau, Gerhild Zauner, Jolanta Lukasiewicz
-
Publication number: 20200339668Abstract: A cross-neutralizing monoclonal antibody that specifically recognizes a cross-reactive epitope of the lipopolysaccharide (LPS) antigen structure of Klebsiella pneumoniae, which is an O3b epitope, cross-reacting with an O3a epitope and an O3 epitope, wherein the antibody is characterized by specific CDR sequences or VH and VL sequences.Type: ApplicationFiled: July 6, 2020Publication date: October 29, 2020Applicants: X4 Pharmaceuticals (Austria) GmbH, Max-Planck-Gesellschaft zur Förderung der Wissenschaften e. V.Inventors: Valeria SZIJÁRTO, Gábor NAGY, Luis GUACHALLA, Katharina RAMONI, Adriana BADARAU, Eszter NAGY, Tim ROLLENSKE, Hedda WARDEMANN, Irina MIRKINA
-
Patent number: 10759848Abstract: A cross-neutralizing monoclonal antibody that specifically recognizes a cross-reactive epitope of the lipopolysaccharide (LPS) antigen structure of Klebsiella pneumoniae, which is an O3b epitope, cross-reacting with an O3a epitope and an O3 epitope, wherein the antibody is characterized by specific CDR sequences or VH and VL sequences.Type: GrantFiled: August 11, 2017Date of Patent: September 1, 2020Assignees: ARSANIS Biosciences GmbH, Max-Planck-Gesellschaft zur Förderung der Wissenschaften e. V.Inventors: Valeria Szijárto, Gábor Nagy, Luis Guachalla, Katharina Ramoni, Adriana Badarau, Eszter Nagy, Tim Rollenske, Hedda Wardemann, Irina Mirkina
-
Publication number: 20190153077Abstract: A cross-neutralizing monoclonal antibody that specifically recognizes a cross-reactive epitope of the lipopolysaccharide (LPS) antigen structure of Klebsiella pneumoniae, which is an O3b epitope, cross-reacting with an O3a epitope and an O3 epitope, wherein the antibody is characterized by specific CDR sequences or VH and VL sequences.Type: ApplicationFiled: August 11, 2017Publication date: May 23, 2019Applicants: ARSANIS Biosciences GmbH, Max-Planck-Gesellschaft zur Förderung der Wissenschaften e. V.Inventors: Valeria SZIJÁRTO, Gábor NAGY, Luis GUACHALLA, Katharina RAMONI, Adriana BADARAU, Eszter NAGY, Tim ROLLENSKE, Hedda WARDEMANN, Irina MIRKINA
-
Publication number: 20190111121Abstract: The subject relates to an isolated antibody that specifically binds to O25b antigen of multi drug resistant (MDR) E. coli strains, its medical and diagnostic use, method of producing the antibody, including an isolated nucleotide sequence, plasmids and host cells as used in the production of the antibody; and further an isolated epitope recognized the specific antibody.Type: ApplicationFiled: December 21, 2018Publication date: April 18, 2019Applicant: ARSANIS BIOSCIENCES GMBHInventors: Eszter NAGY, Gábor NAGY, Valéria SZIJÁRTO, Zoltán MAGYARICS, Irina MIRKINA, Luis GUACHALLA, Adriana BADARAU, Gerhild ZAUNER, Jolanta LUKASIEWICZ
-
Patent number: 10206992Abstract: The subject relates to an isolated antibody that specifically binds to O25b antigen of multi drug resistant (MDR) E. coli strains, its medical and diagnostic use, method of producing the antibody, including an isolated nucleotide sequence, plasmids and host cells as used in the production of the antibody; and further an isolated epitope recognized the specific antibody.Type: GrantFiled: December 9, 2016Date of Patent: February 19, 2019Assignee: ARSANIS BIOSCIENCES GMBHInventors: Eszter Nagy, Gábor Nagy, Valéria Szijárto, Zoltán Magyarics, Irina Mirkina, Luis Guachalla, Adriana Badarau, Gerhild Zauner, Jolanta Lukasiewicz
-
Publication number: 20180298084Abstract: A human or humanized monoclonal IgG antibody (mAb) specifically recognizing the D-galactan-II antigen of Klebsiella pneumoniae O1 which is characterized by a bactericidal CDC activity, its method of production, medical and diagnostic use.Type: ApplicationFiled: October 14, 2016Publication date: October 18, 2018Applicant: ARSANIS BIOSCIENCES GMBHInventors: Eszter NAGY, Gábor NAGY, Valeria SZIJÁRTO, Luis Miguel GUACHALLA, Irina MIRKINA, Zehra VISRAM
-
Publication number: 20180105584Abstract: A monoclonal antibody that counteracts Staphylococcus aureus by specifically binding to wild-type immunoglobulin-binding proteins (IGBP) of S. aureus comprising a cross-specific CDR binding site recognizing at least three of the IGBP domains selected from the group consisting of Protein A (SpA) domains and immunoglobulin-binding protein (Sbi) domains SpA-A, SpA-B, SpA-C, SpA-D, SpA-E, Sbi-I, and Sbi-II, wherein the antibody has an affinity to bind SpA-E with a KD of less than 5×10?9M as determined by a standard optical interferometry method for a F(ab)2 fragment, and preferably binds to wt SpA equally or better compared to mutant SpA-KKAA that lacks binding to IgG Fc or VH3.Type: ApplicationFiled: April 14, 2016Publication date: April 19, 2018Inventors: Eszter NAGY, Adriana BADARAU, Harald ROUHA, Lukas STULIK, Irina MIRKINA, Michael B. BATTLES, Nels NIELSON
-
Patent number: 9914767Abstract: The subject relates to a cross-neutralizing antibody comprising at least one polyspecific binding site that binds to alpha-toxin (Hla) and at least one of the bi-component toxins of Staphylococcus aureus, its medical and diagnostic use, method of producing the antibody, including an isolated nucleotide sequence, plasmids and host cells as used in the production of the antibody; and further an isolated conformational epitope recognized by a specific cross-neutralizing antibody.Type: GrantFiled: April 17, 2013Date of Patent: March 13, 2018Assignee: ARSANIS BIOSCIENCES GMBHInventors: Eszter Nagy, Adriana Badarau, Harald Rouha, Lukas Stulik, Gábor Nagy, Irina Mirkina, Zoltán Magyarics, Zehra Visram, Michaela Jaegerhofer, Manuel Zerbs, Ivana Dolezilkova, Astrid Teubenbacher, Michael Benjamin Battles, Bianka Dominique Prinz
-
Patent number: 9849169Abstract: The subject relates to an isolated antibody that specifically binds to O25b antigen of multi drug resistant (MDR) E. coli strains, its medical and diagnostic use, method of producing the antibody, including an isolated nucleotide sequence, plasmids and host cells as used in the production of the antibody; and further an isolated epitope recognized the specific antibody.Type: GrantFiled: January 17, 2014Date of Patent: December 26, 2017Assignee: ARSANIS Biosciences GmbHInventors: Eszter Nagy, Gábor Nagy, Valéria Szijárto, Zoltán Magyarics, Irina Mirkina, Luis Guachalla, Adriana Badarau, Gerhild Zauner, Jolanta Lukasiewicz
-
Publication number: 20170087236Abstract: The subject relates to an isolated antibody that specifically binds to O25b antigen of multi drug resistant (MDR) E. coli strains, its medical and diagnostic use, method of producing the antibody, including an isolated nucleotide sequence, plasmids and host cells as used in the production of the antibody; and further an isolated epitope recognized the specific antibody.Type: ApplicationFiled: December 9, 2016Publication date: March 30, 2017Applicant: ARSANIS BIOSCIENCES GMBHInventors: Eszter NAGY, Gábor NAGY, Valéria SZIJÁRTO, Zoltán MAGYARICS, Irina MIRKINA, Luis GUACHALLA, Adriana BADARAU, Gerhild ZAUNER, Jolanta LUKASIEWICZ
-
Publication number: 20160340415Abstract: The invention provides for an antibody comprising at least one binding site that specifically binds to a LukGH complex, which antibody comprises at least an antibody heavy chain variable region (VH), which comprises any of the CDR1 to CDR3 sequences as listed in Table 1, or functionally active CDR variants thereof.Type: ApplicationFiled: December 19, 2014Publication date: November 24, 2016Inventors: Eszter NAGY, Adriana BADARAU, Harald ROUHA, Irina MIRKINA, Michael Benjamin BATTLES, Laura M. WALKER, Nels NIELSON, S. Jain TUSHAR
-
Publication number: 20160244511Abstract: The invention refers to a cross-neutralizing antibody comprising at least one polyspecific binding site that binds to alpha-toxin (Hla) and at least one of the bi-component toxins of Staphylococcus aureus, which antibody comprises at least three complementarity determining regions (CDR1 to CDR3) of the antibody heavy chain variable region (VH), wherein A) the antibody comprises a) a CDR1 comprising or consisting of the amino acid sequence YSISSGMGWG (SEQ ID 1); and b) a CDR2 comprising or consisting of the amino acid sequence SIDQRGSTYYNPSLKS (SEQ ID 2); and c) a CDR3 comprising or consisting of the amino acid sequence ARDAGHGVDMDV (SEQ ID 3); or B) the antibody comprises at least one functionally active CDR variant of a) the parent CDR1 consisting of the amino acid sequence of SEQ ID 1; or b) the parent CDR2 consisting of the amino acid sequence of SEQ ID 2; or c) the parent CDR3 consisting of the amino acid sequence of SEQ ID 3; wherein the functionally active CDR variant comprises at least one point mutatiType: ApplicationFiled: October 17, 2014Publication date: August 25, 2016Inventors: Eszter NAGY, Adriana BADARAU, Harald ROUHA, Gabor NAGY, Irina MIRKINA, Zoltan MAGYARICS, Zebra VISRAM, Michael Benjamin BATTLES, Bianka Dominique PRINZ, Tushar S. JAIN
-
Publication number: 20150322138Abstract: The subject relates to an isolated antibody that specifically binds to O25b antigen of multi drug resistant (MDR) E. coli strains, its medical and diagnostic use, method of producing the antibody, including an isolated nucleotide sequence, plasmids and host cells as used in the production of the antibody; and further an isolated epitope recognized the specific antibody.Type: ApplicationFiled: January 17, 2014Publication date: November 12, 2015Inventors: Eszter NAGY, Gábor NAGY, Valéria SZIJÁRTO, Zoltán MAGYARICS, Irina MIRKINA, Luis GUACHALLA, Adriana BADARAU, Gerhild ZAUNER, Jolanta LUKASIEWICZ
-
Publication number: 20150086539Abstract: The subject relates to a cross-neutralizing antibody comprising at least one polyspecific binding site that binds to alpha-toxin (Hla) and at least one of the bi-component toxins of Staphylococcus aureus, its medical and diagnostic use, method of producing the antibody, including an isolated nucleotide sequence, plasmids and host cells as used in the production of the antibody; and further an isolated conformational epitope recognized by a specific cross-neutralizing antibody.Type: ApplicationFiled: April 17, 2013Publication date: March 26, 2015Inventors: Eszter Nagy, Adriana Badarau, Harald Rouha, Lukas Stulik, Gábor Nagy, Irina Mirkina, Zoltán Magyarics, Zehra Visram, Michaela Jaegerhofer, Manuel Zerbs, Ivana Dolezilkova, Astrid Teubenbacher, Michael Benjamin Battles, Bianka Dominique Prinz